LoginSignup
Beyond logo

Beyond

Stock
Stock
ISIN: US08862L1035
Ticker: XAIR
US08862L1035
XAIR

Price

Price

Frequently asked questions

What is Beyond's market capitalization?

The market capitalization of Beyond is $37.49M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is the Earnings Per Share (EPS) for Beyond?

Beyond's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$1.42. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Beyond's stock?

Currently, 6 analysts cover Beyond's stock, with a consensus target price of $11.67. Analyst ratings provide insights into the stock's expected performance.

What is Beyond's revenue over the trailing twelve months?

Over the trailing twelve months, Beyond reported a revenue of $2.34M.

What is the EBITDA for Beyond?

Beyond's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$53.24M. EBITDA measures the company's overall financial performance.

What is the free cash flow of Beyond?

Beyond has a free cash flow of -$55.19M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of Beyond's stock?

The 5-year beta for Beyond is -0.22. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does Beyond have, and what sector and industry does it belong to?

Beyond employs approximately 107 people. It operates in the Health Care sector, specifically within the Medical Equipment & Supplies industry.

What is the free float of Beyond's shares?

The free float of Beyond is 60.38M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 $37.49M

5Y beta

 -0.22

EPS (TTM)

 -$1.42

Free Float

 60.38M

Revenue (TTM)

 $2.34M

EBITDA (TTM)

 -$53.24M

Free Cashflow (TTM)

 -$55.19M

Pricing

1D span
$0.508$0.559
52W span
$0.296$2.36

Analyst Ratings

The price target is $11.67 and the stock is covered by 6 analysts.

Buy

6

Hold

0

Sell

0

Information

Beyond Air, Inc. is a commercial stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received United States Food and Drug Administration (FDA) approval for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. It is advancing its other LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19), and nontuberculous mycobacteria (NTM) among others. It has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder (ASD) and other neurological disorders. Its approved product and active pipeline of product candidates include LungFit PH, LungFit PRO and LungFit GO.

107

Medical Equipment & Supplies

Health Care

Identifier

ISIN

US08862L1035

Primary Ticker

XAIR

Knockouts

Join the conversation
Sign upLogin